Liquid Biopsies and the Potential to Make Tissue Less of an IssueMonday, 16 November 2015 at 09:30 Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com Blood-based testing can reduce test turnaround time and potentially serve as a surrogate for tissue for biopsy ineligible or fragile patients, for whom a tissue sample is not available. Potential uses being explored in clinical studies and trials include 1) identification of genetic determinants that direct targeted therapies (eg EGFR activating mutations in NSCLC for several tyrosine kinase inhibitors), 2) evaluation of early treatment responses, 3) monitoring for minimal residual disease and 4) assessment of disease progression and resistance development. Several technologies are in development for blood based analytes including circulating tumor cells, contents of exosomes released by cancer cells, and cell free circulating tumor DNA (ctDNA). This presentation will exemplify the potential power of Liquid Biopsy approaches using ctDNA analyses with data from several clinical studies involving NSCLC patients undergoing targeted therapy treatment. Liquid Biopsies and the Potential to Make Tissue Less of an IssueMonday, 16 November 2015 at 09:30 Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com Blood-based testing can reduce test turnaround time and potentially serve as a surrogate for tissue for biopsy ineligible or fragile patients, for whom a tissue sample is not available. Potential uses being explored in clinical studies and trials include 1) identification of genetic determinants that direct targeted therapies (eg EGFR activating mutations in NSCLC for several tyrosine kinase inhibitors), 2) evaluation of early treatment responses, 3) monitoring for minimal residual disease and 4) assessment of disease progression and resistance development. Several technologies are in development for blood based analytes including circulating tumor cells, contents of exosomes released by cancer cells, and cell free circulating tumor DNA (ctDNA). This presentation will exemplify the potential power of Liquid Biopsy approaches using ctDNA analyses with data from several clinical studies involving NSCLC patients undergoing targeted therapy treatment. |